HIV-related non-Hodgkin's lymphoma: CHOP-induction and AZT/IF alpha-maintenance therapy (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

HIV-related non-Hodgkin's lymphoma: CHOP-induction and AZT/IF alpha-maintenance therapy (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A12 1993. Unique Identifier : AIDSLINE ICDB/93694412
Huhn D; Weiss R; Nerl C; Mitrou S; Schurmann D; Arasteh K; Kronawitter U; Becker K; van Lunzen J; UKRV, Berlin, Germany

Abstract: In a pilot study, induction therapy with CHOP and maintenance therapy with IF alpha and AZT were tested. High- and normal-risk patients (pts) were identified. Methods: High risk, 2 of 3 criteria: T4 less than 50 ul; WHO PS 3 + 4; opportunistic infection. Normal risk: high risk criteria not met and no Stage IA or primary CNS involvement. Induction treatment in normal risk: 4-6 cycles of CHOP; CNS prophylaxis. Maintenance treatment: AZT 500 mg daily and IF alpha 5 x 10(6) U sc 3x/wk for 12 mo. Supplemental treatment: aerosol pentamidine; G-CSF according to a fixed scheme considering leukocyte values. Induction treatment in high-risk: weekly VCR and prednisone. 107 pts from 15 institutions were registered from January 1991 to November 1992: 9 pts high risk, 38 normal risk, 60 pts not treated according to protocol (11 pts primary CNS, 4 Stage IA, 13 not NHL histology [Hodgkin's, MM, ALL], 8 final stage or incurable infection, 12 diagnosis postmortem, 5-second malignancies, 7 no pt approval). Mean values of T4, T8, T4/T8 lymphocytes/ul in high-risk pts: 16, 314, 0.04; in normal-risk: 193, 812, 0.2. Results of induction therapy were CR in 18/28 (64%) and PR in 6/28 (10 pts too early for evaluation). High-risk: No remissions. Median survival in high-risk is 82 days, in normal-risk 641 days. CHOP and AZT/IF alpha therapy are well tolerated. The course of immune parameters depends on the state of remission.

Keywords: Acquired Immunodeficiency Syndrome/MORTALITY/PATHOLOGY/*THERAPY Antineoplastic Agents, Combined/*THERAPEUTIC USE Combined Modality Therapy Cyclophosphamide/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Follow-Up Studies Granulocyte Colony-Stimulating Factor/ADMINISTRATION & DOSAGE Human Interferon-alpha/*ADMINISTRATION & DOSAGE Lymphoma, AIDS-Related/MORTALITY/PATHOLOGY/*THERAPY Neoplasm Staging Pilot Projects Prednisone/ADMINISTRATION & DOSAGE Survival Rate Vincristine/ADMINISTRATION & DOSAGE Zidovudine/*THERAPEUTIC USE ABSTRACT
931230
M93C0805

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .